Sub-Group I: Data Science and TechnologyFlow vs NGS MRD – At the beginning

Sub-Group I: Data Science and Technology

Flow vs NGS MRD - Now

Sub-Group I: Data Science and TechnologyMinimal Residual DISEASE

Sub-Group II: Meta-Analyses

Munshi N et al., JAMA Oncol, in press

Sub-Group II: Meta-Analyses

How much is enough?

“You must not use a steam hammer to crack a nut if a nutcracker will do”- Lord Diplock

Sub-Group IIIA: Trial Designs – New Drugs Evidence

Regular Approval

PFS/OS

Single Trial Model

Surrogate/ MRD Accelerated

Approval

Regular Approval

Multiple Trial Model

Surrogate/ MRD Accelerated Approval

Sub-Group IIIB: Changing Clinical Practice with Existing Drugs

New IMWG Criteria that include MRD

Kumar S, et al. Lancet Oncol; in press.

Sub-Group IIIB: Changing Clinical Practice with Existing Drugs

Impact on patients?